Kelsey Goodwin
Stock Analyst at Guggenheim
(1.43)
# 1,329
Out of 4,497 analysts
11
Total ratings
42.86%
Success rate
-8.38%
Average return
Main Sectors:
Top Industries:
6 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NUVL Nuvalent | Assumes: Buy | $99 | $78.96 | +25.38% | 1 | Feb 28, 2024 | |
| TSVT 2seventy bio | Downgrades: Neutral | n/a | $4.47 | - | 4 | Sep 13, 2023 | |
| ACLX Arcellx | Maintains: Buy | n/a | $62.56 | - | 3 | Jun 20, 2023 | |
| LEGN Legend Biotech | Initiates: Neutral | n/a | $58.74 | - | 1 | Oct 31, 2022 | |
| IOVA Iovance Biotherapeutics | Initiates: Neutral | n/a | $7.96 | - | 1 | Oct 31, 2022 | |
| IPSC Century Therapeutics | Initiates: Buy | $15 | $2.50 | +500.00% | 1 | Oct 31, 2022 |
Nuvalent
Feb 28, 2024
Assumes: Buy
Price Target: $99
Current: $78.96
Upside: +25.38%
2seventy bio
Sep 13, 2023
Downgrades: Neutral
Price Target: n/a
Current: $4.47
Upside: -
Arcellx
Jun 20, 2023
Maintains: Buy
Price Target: n/a
Current: $62.56
Upside: -
Legend Biotech
Oct 31, 2022
Initiates: Neutral
Price Target: n/a
Current: $58.74
Upside: -
Iovance Biotherapeutics
Oct 31, 2022
Initiates: Neutral
Price Target: n/a
Current: $7.96
Upside: -
Century Therapeutics
Oct 31, 2022
Initiates: Buy
Price Target: $15
Current: $2.50
Upside: +500.00%